NO20011966L - Serin-protease-inhibitor - Google Patents

Serin-protease-inhibitor

Info

Publication number
NO20011966L
NO20011966L NO20011966A NO20011966A NO20011966L NO 20011966 L NO20011966 L NO 20011966L NO 20011966 A NO20011966 A NO 20011966A NO 20011966 A NO20011966 A NO 20011966A NO 20011966 L NO20011966 L NO 20011966L
Authority
NO
Norway
Prior art keywords
protease inhibitor
serine protease
serine
inhibitor
protease
Prior art date
Application number
NO20011966A
Other languages
English (en)
Norwegian (no)
Other versions
NO20011966D0 (no
Inventor
Cornelis Marius Timmers
Johannes Bernardus Ma Rewinkel
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO20011966D0 publication Critical patent/NO20011966D0/no
Publication of NO20011966L publication Critical patent/NO20011966L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NO20011966A 1998-10-23 2001-04-20 Serin-protease-inhibitor NO20011966L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203559 1998-10-23
PCT/EP1999/007928 WO2000024718A1 (en) 1998-10-23 1999-10-19 Serine protease inhibitor

Publications (2)

Publication Number Publication Date
NO20011966D0 NO20011966D0 (no) 2001-04-20
NO20011966L true NO20011966L (no) 2001-04-23

Family

ID=8234249

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011966A NO20011966L (no) 1998-10-23 2001-04-20 Serin-protease-inhibitor

Country Status (24)

Country Link
US (1) US6903107B1 (id)
EP (1) EP1123280A1 (id)
JP (1) JP2002528438A (id)
KR (1) KR20010075648A (id)
CN (1) CN1146543C (id)
AR (1) AR020922A1 (id)
AU (1) AU763667B2 (id)
BR (1) BR9914694A (id)
CA (1) CA2346990A1 (id)
CO (1) CO5140114A1 (id)
CZ (1) CZ20011440A3 (id)
HU (1) HUP0103806A3 (id)
ID (1) ID29885A (id)
IL (1) IL142398A0 (id)
NO (1) NO20011966L (id)
NZ (1) NZ511067A (id)
PE (1) PE20001283A1 (id)
PL (1) PL347948A1 (id)
RU (1) RU2232760C2 (id)
SK (1) SK5372001A3 (id)
TR (1) TR200101120T2 (id)
TW (1) TW575567B (id)
WO (1) WO2000024718A1 (id)
ZA (1) ZA200102970B (id)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10046272A1 (de) * 2000-09-19 2002-03-28 Merck Patent Gmbh Aminoheterocyclen (Faktor Xa Inhibitoren 14)
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CN100513398C (zh) 2002-12-03 2009-07-15 Axys药物公司 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
EP1899322B1 (en) * 2005-06-28 2009-09-02 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
HRP20110839T1 (hr) 2005-07-26 2011-12-31 Sanofi Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze
PT1910333E (pt) 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
TWI389899B (zh) * 2006-08-08 2013-03-21 Msd Oss Bv 具口服活性之凝血酶抑制劑
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
BRPI0720710A2 (pt) * 2006-12-27 2014-12-23 Sanofi Aventis Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina
JP5421783B2 (ja) * 2006-12-27 2014-02-19 サノフイ Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
CN101595094B (zh) * 2006-12-27 2013-02-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮衍生物
ATE502027T1 (de) 2006-12-27 2011-04-15 Sanofi Aventis Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
KR20090094338A (ko) * 2006-12-27 2009-09-04 사노피-아벤티스 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
AU2007338410B2 (en) 2006-12-27 2012-08-16 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
EP2102164B1 (en) * 2006-12-27 2010-12-01 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
MX2010012442A (es) 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
PL2313374T3 (pl) 2008-06-24 2014-03-31 Sanofi Sa 6-podstawione izochinoliny i izochinolinony
PE20110059A1 (es) * 2008-06-24 2011-02-15 Sanofi Aventis Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa
SI2303845T1 (sl) * 2008-06-24 2013-12-31 Sanofi Bi- in policiklični substituirani izokinolin in izokinolinski derivati kot inhibitorji rho-kinaze
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
SMT201900520T1 (it) * 2011-06-28 2019-11-13 Inhibrx Lp Polipeptidi di fusione serpinici e relativi metodi d'uso
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
RU2639526C2 (ru) * 2011-06-28 2017-12-21 ИНХИБРКС ЭлЭлСи Слитые полипептиды, содержащие домен wap, и способы их применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473501A (en) 1981-05-04 1984-09-25 G. D. Searle & Co. Dihydro azino isoquinolines
GB8908229D0 (en) * 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
BR9708607A (pt) * 1996-04-13 1999-08-03 Astra Pharma Prod Composto composição farmacéutica utilização de um composto processo para tratamento ou redução do risco de doença inflamatória num paciente e para a preparação de um composto e intermediário químico
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
AU753675B2 (en) * 1998-03-19 2002-10-24 Ajinomoto Co., Inc. Aminoisoquinoline derivatives

Also Published As

Publication number Publication date
WO2000024718A1 (en) 2000-05-04
HUP0103806A2 (hu) 2002-02-28
ZA200102970B (en) 2002-07-10
PL347948A1 (en) 2002-04-22
ID29885A (id) 2001-10-18
AU763667B2 (en) 2003-07-31
CA2346990A1 (en) 2000-05-04
JP2002528438A (ja) 2002-09-03
KR20010075648A (ko) 2001-08-09
CO5140114A1 (es) 2002-03-22
RU2232760C2 (ru) 2004-07-20
PE20001283A1 (es) 2000-11-20
AU6341399A (en) 2000-05-15
NO20011966D0 (no) 2001-04-20
AR020922A1 (es) 2002-06-05
HUP0103806A3 (en) 2002-03-28
NZ511067A (en) 2003-03-28
BR9914694A (pt) 2001-07-10
TW575567B (en) 2004-02-11
IL142398A0 (en) 2002-03-10
CZ20011440A3 (cs) 2001-09-12
CN1348444A (zh) 2002-05-08
SK5372001A3 (en) 2001-11-06
CN1146543C (zh) 2004-04-21
TR200101120T2 (tr) 2001-08-21
US6903107B1 (en) 2005-06-07
EP1123280A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
NO20011966D0 (no) Serin-protease-inhibitor
ATE264339T1 (de) Serine protease inhibitoren
NO20012980L (no) Proteaseinhibitorer
NO992734L (no) Serin-protease inhibitorer
NO995433D0 (no) Protease-inhibitorer
NO983688D0 (no) Serin-protease-inhibitorer
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
ID25897A (id) Variant-variant protease tersubstitusi banyak
NO20004696D0 (no) Kinoloner som serinproteaseinhibitorer
DE69730871D1 (de) Serine-protease-inhibitoren
NO995435D0 (no) Protease-inhibitorer
DK0886647T3 (da) Serinproteasehæmmere
NO995268D0 (no) Proteaseinhibitorer
NO995434L (no) Proteaseinhibitorer
IS5590A (is) Bensoxasínón/bensóþíasínón notuð sem serínprótínkljúfatálmar
DE59806475D1 (de) Urokinase-inhibitoren
GB9800817D0 (en) Serine protease inhibitors
NO20011388L (no) Hydroksamat-inneholdende cystein- og serinproteasehemmere
DZ2815A1 (fr) Inhibiteurs de protéase.
DE69903779D1 (de) Inhibitor- Schalter
EP1206233A4 (en) Serine proteases
EP1132473A4 (en) NEW SERINE PROTEASE BSSP6
EP0949334A4 (en) NEW SERINE PROTEASE.
EP1195163A4 (en) Serine protease inhibitors
MA26429A1 (fr) Inhibiteurs de protease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application